Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Postmarketing Observational Study to Evaluate the Safety of ADASUVE® (STACCATO® Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder

NCT03513549 is registered in ClinicalTrials.gov with Alexza Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03513549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03513549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Postmarketing Observational Study to Evaluate the Safety of ADASUVE® (STACCATO® Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder
Lead sponsor
Alexza Pharmaceuticals, Inc.
Phase
Observational
Overall status
Suspended
Start date
November 4, 2014
Completion date
September 30, 2027
Enrollment
10,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

agitation,psychomotor